Emerging SARS-CoV-2 Mutations: Impact on TaqPath Assay Performance and its Clinical Implications
SARS-CoV-2 has been mutating at a rate of about one to two mutations per month. The Centers for Disease Control and Prevention (CDC) reports that multiple variants of the virus are now circulating globally, including P.1 (Brazil), B.1.351 (South Africa), and B.1.1.7 (United Kingdom). What makes the new B.1.1.7. UK variant different is that it seems to have acquired mutations much more quickly than scientists expected, resulting in a reported 70% increase in transmissibility.
The emergence of multiple SARS-CoV-2 variants brings fast-moving questions for clinical laboratory administrators about the ability to identify new potential coronavirus SARS-CoV-2 variants. One of the most notable is how standard COVID-19 testing can be positioned to detect these new variants, particularly now that the S-gene dropout issue has been discovered.
During this complimentary webinar with follow-up Q&A, you will hear about the important clinical implications (epidemiological, prognostic, and predictive) of these “variants of concern,” the importance of early detection of these variants, and the steps your lab can take to confidently detect the COVID-19 virus with a very high degree of specificity and sensitivity, and identify the S-gene dropout.
Attend this 60-minute program, and you will:
- Get key insights into the novel SARS-CoV-2 strains including the UK variant (B.1.1.7) and the South African variant (B.1.351/501Y.V2) and the significant mutations associated with these variants
- Understand automation and miniaturization of clinical SARS-CoV-2 RT-qPCR testing for population genomic surveillance
- Learn how the TaqPath workflow addresses the S-gene dropout issue by detecting this unique variant
- Discover how the mutations in these “variants of concern” are relevant to the different TaqPath COVID-19 assays
- Be briefed on how UCSD and Scripps are collaborating to deliver rapid and cost-effective genomic epidemiology to public health officials, and much more
Who should attend?
- Clinical laboratory directors
- Laboratory managers
- Clinical pathologists
- Laboratory technicians
- Anyone involved in clinical laboratory testing
Your registration includes:
- A site license to attend the webinar. Invite as many members of your team as you would like!
- The opportunity to pose specific questions, and connect directly with the panel, during a Q&A session
With your attendance of this webinar:
- Learn about how your clinical laboratory can best serve the senior care segment
- Gain insights into the most effective and efficient ways to connect to and support long-term care customers
- Find out what your lab should look for in an integration partner
- Hear new ways to grow and retain your lab business
Due to the threat of enhanced transmissibility, SARS-CoV-2 viral mutations are such a concern that the US Food and Drug Administration (FDA) issued an alert to clinical laboratory staff and healthcare providers that variants may potentially impact SARS-CoV-2 molecular tests, and is taking action to ensure authorized COVID-19 diagnostic tests remain accurate.
Attend this important webinar and learn what your lab needs to know now.
Peter De Hoff, PhD
Department of Reproductive Medicine
Sanford Consortium for Regenerative Medicine
UC San Diego
La Jolla, CA
Manoj Gandhi, MD, PhD
Senior Medical Director
Thermo Fisher Scientific
South San Francisco, CA
Andersen and Su labs
La Jolla, CA
UC San Diego
San Diego, CA